Business of DNA

DNA Direct Announces DNA Perspectives

by Dr. Hsien-Hsien Lei
Posted April 18, 2008 in Business of DNA, DNA Testing

An editorial in the April 10, 2008 issue of Nature discusses “transparency and honesty” in the genetic testing industry. One suggestion was to create a registry in lieu of greater federal regulation. Such a registry would include data about genetic tests and the evidence that supports making such tests commercially available.

Such a registry should be international, harmonizing information in what will doubtless be an industry without borders. This approach seems preferable to stepped-up regulation by agencies such as the Food and Drug Administration (FDA), which — in addition to travelling at the snail’s pace of bureaucracy rather than the lightning speed of burgeoning markets — could easily have the effect of driving less-than-desirable players underground, where sub-standard tests will remain as easy to buy as black-market DVDs.

dna directDaniel MacArthur at Genetic Future has more on the editorial. I’ve also helped DNA Direct, where I work as a genetic information specialist, write a response to the editorial (pdf) in which we announce the DNA Perspectives initiative.

DNA Perspectives will be a collaborative site developed by a wide range of industry experts to objectively evaluate the clinical validity and utility of genetic markers as well as commercially available genetic tests.

Unlike other genetics resources currently available on the Web, DNA Perspectives is designed specifically to assist consumers in evaluating genetic discoveries and commercially available genetic tests with the use of our exclusive rating system. A DNA Perspectives wiki with the latest and most relevant genetics information will be created and maintained by invited genetics experts. DNA Perspectives will be available to the public for free. It is based on the principles of the open source movement: transparency, permeable access, and collaboration. In addition, a special forum will be open to consumers for their comments and personal ratings of genetic tests.

If you’re interested in being updated as DNA Perspectives develops or perhaps becoming involved as an expert contributor, you can submit your email at the DNA Perspectives page.

(5 comments)


goldfade-divider-custom.gif

Affymetrix and Illumina Moving Gene Chip Manufacturing to Singapore

by Dr. Hsien-Hsien Lei
Posted March 19, 2008 in Business of DNA, DNA Around the World

beltsHere’s one more sign that companies involved with personal genomics may be tightening their belts. Gene chip makers Affymetrix and Illumina are both outsourcing manufacturing from the U.S. to Singapore.

Affymetrix president Kevin King:

Affymetrix is consolidating its manufacturing operations to further increase operational efficiencies, enabling us to remain more competitive in the marketplace. Our recent manufacturing advances have enabled us to produce more (GeneChip) array volumes with a smaller manufacturing footprint.

One of the Affymetrix products to be manufactured in Singapore is the new Genome-Wide Human SNP Array 6.0, which can analyze more than 1.8 million DNA markers.

Affymetrix has already begun laying off workers in their West Sacramento, California manufacturing plant and will be making the move to Singapore by the end of 2008 where they opened a 150,000-square-foot manufacturing plant in 2006. Possible reasons for outsourcing genetic test manufacturing to Singapore include:

  • Cheaper labor costs – production workers in Singapore averaged $8.55/hour in 2006 compared to $23.82 per hour in the U.S.
  • Lower tax rates
  • Faster-growing demand for arrays in China and India make manufacturing in Singapore more cost effective

China’s genomic biotechnology is definitely on the rise. At the beginning of this year, the Beijing Genomics Institute (BGI) announced the complete sequencing of the fourth human genome in the world. BGI also formed a partnership with whole genome sequencing company, Knome. In terms of the local personal genomics markets in China and India, there may be great potential but not for the vast majority of people. For the time being, only the rich and famous in developing countries will have access and the chance to be “exploited” like the rest of the elite, according to Jesse Reynolds at The Cutting Edge News.

In the end, it’s all about the bottom line. Affymetrix chief financial officer John Batty:

I think from an economics standpoint, we have an incentive to get it to at least 50 percent [of Singapore plant capacity] because we can shield half of our revenue from the U.S. tax rate by manufacturing arrays in Singapore and shipping those to non-U.S. customers.

I have no doubts about Singapore producing high quality products for use in genetics/genomics. On the other hand, when outsourcing extends to China and other countries with a less educated workforce, it would be worth remembering that standards of quality control vary between countries. For proof, check out what writer James Fallows observed with airplane refueling techniques in Japan vs. China.

plane refueling japanplane refueling china

Hey, whatever gets the job done, right?

(>> Start a discussion!)


goldfade-divider-custom.gif

deCODE CEO Predicts Downswing in Personal Genomics Market

by Dr. Hsien-Hsien Lei
Posted March 5, 2008 in Business of DNA, DNA Testing

pink slip cakeWith the many genomics and genetics companies launching left, right, and center in recent months, you’d think the market is pretty robust. Not so, says deCODE CEO Kari Stefansson whose company is laying off 60 employees out of a total of 390 or about 15% of its workforce.

It is natural for us to operate the company in such a way that we can make the money that we have last longer than what we had expected to begin with. These are very simple and clear operational standpoints and it would even be wise for other companies in our community to follow our example. [emphasis added]

If what Stefansson says is true, then others like 23andMe, Navigenics, and DNATraits might be looking to tighten operations as well. Although it appears that most personal genomics companies operate with small staffs of less then 50-100, downturns in the market could mean that work is outsourced to independent contractors rather than being performed by full-time employees. (So if you’re looking for a job in the genomics industry, you know how to approach it.) However, not all companies suffer from as much pessimism as deCODE. bizjournals reported last week that Family Tree DNA led by Bennett Greenspan and Max Blankfeld saw a profit gross revenue of around $12.2 million in 2006.

deCODE is behind several genetics products available direct to consumers including:

  • deCODEme – A whole genome scan using Affymetrix DNA chips to analyzing over one million single nucleotide polymorphisms (SNPs) per customer.
  • deCODE T2 – A genetic test for type 2 diabetes that detects a variation in the TCF7L2 gene.
  • deCODE MI – A genetic test for myocardial infarction (aka heart attack, coronary artery thrombosis, or coronary artery occlusion).
  • deCODE Glaucoma – A genetic test for exfoliation glaucoma that detects SNPs located in the LOXL1 gene on chromosome 15. (For more, see this Eye on DNA post.)
  • deCODE ProCa (previously named deCODE PrCa) – A genetic test for prostate cancer.

Given their wide range of products, it’s surprising that deCODE is suffering from cash flow problems in which earnings, balance sheet, and profits from markets are not enough for them to continue growing. Perhaps this is an indication that the market is starting to experience saturation in the number of companies and services being offered yet has not seen a concomitant rise in the number of consumers willing to pay for personal genomic services.

What’s more interesting is that the price of technology continues to drop. BusinessWeek surveyed the DNA sequencing market and found that new technologies are faster and cheaper. Soon we will even have the coveted $1,000 genome. This means that companies should have to spend less to earn more. For example, Illumina’s margins are declining and their revenues are expected to rise 35% in 2008. And production costs will continue drop as labs open up in countries with lower overhead, e.g., China. So shouldn’t it be easier to make a profit now off of personal genomics than ever before?

In any case, while 23andMe and Knome focus on the rich, famous, and elite, there is a great need to show the general public how genetic testing of all types is relevant to their everyday lives. There aren’t enough millionaires like Dan Stoicescu to fund the entire personal genomics market. Until genetic testing is widely adopted for a variety of commercial uses by a greater segment of the consumer population, the pot of profits will not be big enough to share. In 2008, we will surely see companies drop out and others consolidate.

HT: The Genetic Genealogist, GENEALOGY-DNA

(14 comments)


goldfade-divider-custom.gif

China Now Exporting Genomic Biotechnology

by Dr. Hsien-Hsien Lei
Posted January 14, 2008 in Business of DNA, DNA Around the World

beijing 2008Early last week, Beijing Genomics Institute (BGI) announced the complete sequencing of the fourth human genome in the world. Later the same week, whole genome sequencing company, Knome, announced a partnership with BGI where BGI will provide genome sequencing, assembly, and annotation capabilities. Knome will be responsible for analytic tools, security protocols, and genetic interpretation services. According the press release, BGI has over 120 sequencing machines, 10 supercomputers, and 500 terabytes of storage.

Given all the quality control issues surrounding Chinese-made products in Summer 2007, I wouldn’t blame anyone for doubting the quality of genomics in China as well. And although I’d already placed my bets on Singapore being the biotech hub of Asia because of my own positive experience with science in Singapore and scientists from the city state, it appears that I may be mistaken.

Nature Biotechnology reports that China is making great strides in health biotech and with a billion-patient market, who can resist? Shenzhen SiBiono GeneTech Co. developed Gendicine, the world’s first commercialized gene therapy for head and neck cancers. Shanghai United Cell Biotech is making the only tablet cholera vaccing available worldwide. Other Chinese biotech companies are working on vaccines for HIV, Japanese Encephalitis, SARS, and pandemic avian influenza (H5N1). And, of course, BGI has been sequencing genomes.

Development of health-related biotechnology in China is not without its obstacles. Some of the issues raised include:

  • China’s uncertain financial system
  • Rigid restrictions on exports
  • Quality control
  • Intellectual property rights
  • Lack of trust between China-based and international partners
  • Barriers created by language, travel, culture, and project management styles.

For biotechnology companies looking to expand their business in China, Stephen M. Sammut of Burril & Company has this advice:

…the country’s industry might be better served if Chinese residents in the West built transnational companies with a footprint in both China and the West.

While this practice is already common, regulations and taxation policies to encourage this approach would address many of the concerns of private and public capital, assure prospective alliance partners, and add depth to the pool of experienced managers. Such an approach would also promote China as a co-development partner rather than a purely low-cost venue to international companies to contract services.

So it appears that Knome is on the cutting edge of both genomics and international business. Because labor costs in China are much lower than in the US, partnering with BGI will surely improve the bottom line as well. Another smart move for a company that’s charging $350,000 and more for whole genome sequencing.

via Innovations Report

Tags: , , , , , , , , ,

(3 comments)


goldfade-divider-custom.gif

Singapore Biotech Sector Loses Stem Cell Researcher Alan Colman

by Dr. Hsien-Hsien Lei
Posted December 18, 2007 in Business of DNA, DNA in General

Singapore, with its well-educated, English-speaking population, has long been thought of as a potential Asian hub of biotech research and business. Up till now, many of the top tier scientists leading the biotech effort in the country have been recruited from overseas, including British scientist Alan Colman who was a member of the team that cloned Dolly the sheep.

Now Alan Colman is leaving Singapore for King’s College London following the departure of molecular and cell biologists David and Birgitte Lane for Scotland’s University of Dundee. Dr. Colman was executive director of the Singapore Stem Cell Consortium. Last year, the World Bank gave Singapore a 50-50 chance of success in the biomedical arena because of an overreliance on “footloose” star researchers rather than local scientists.

merlion singapore

According to Reuters, Singapore has invested more than 2 billion US dollars in the biomedical sector. They’ve encouraged start-up companies, new labs, and welcomed controversial projects, such as stem cell research. Although Colman and the Lanes claim they will continue to spend a significant amount of time in Singapore, there are doubts that they will be able to accomplish much for the local sector in such limited amounts of time.

Despite this set of bad news, I’m not convinced the situation is so dire. I personally know of companies in Singapore who are on the cutting edge of genomic technology and research. In addition, a number of my classmates at Stanford and Johns Hopkins were from Singapore (including my husband!) and returned to the country to work for locally-owned, international companies or to conduct research. My family and I will be living in Singapore in the future and I look forward to finding out for myself all the many opportunities available there.

If you’re involved in the Singapore biotech sector, I’d love to learn more about the situation there. Please email me!

via Tomorrow

Tags: , , , , , , ,

(6 comments)


goldfade-divider-custom.gif

Next »

Search Eye on DNA


Enter your email address:

Delivered by FeedBurner


ARCHIVE


RANDOMIZED BLOGROLL


We comply with the HONcode standard for trustworthy health
information:
verify here.
Eye on DNA is not a substitute for medical advice. Always ask your healthcare provider or genetic counselor for information specific to you.

Mendel's Garden

Healthcare 100 - eDrugSearch.com



View Hsien-Hsien Lei, PhD's profile on LinkedIn

Bloggers' Rights at EFF